VIRULENCE FACTORS AND SUSCEPTIBILITY OF CANDIDA SPP. CAUSATIVE AGENTS OF NEONATAL INFECTIONS

Similar documents
Antifungal Treatment in Neonates

Antifungals and current treatment guidelines in pediatrics and neonatology

National Center for Emerging and Zoonotic Infectious Diseases AR Lab Network Candida Testing

9/18/2018. Invasive Candidiasis. AR Lab Network Candida Testing. Most Common Healthcare Associated Bloodstream Infection in the United States?

Antifungal Stewardship. Önder Ergönül, MD, MPH Koç University, School of Medicine, Istanbul 6 October 2017, ESGAP course, Istanbul

Candida auris: an Emerging Hospital Infection

Update zu EUCAST 2012 Cornelia Lass-Flörl

When is failure failure?

Table 1. Antifungal Breakpoints for Candida. 2,3. Agent S SDD or I R. Fluconazole < 8.0 mg/ml mg/ml. > 64 mg/ml.

Fungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia

MALDI-TOF Mass Spectrometry: A New Rapid ID Method in Clinical Microbiology

Introduction. Study of fungi called mycology.

MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS

An Update in the Management of Candidiasis

Case Studies in Fungal Infections and Antifungal Therapy

Candida auris - an update on a globally emerging pathogen

Condition First line Alternative Comments Candidemia Nonneutropenic adults

BSI. Candida auris: A globally emerging multidrug-resistant yeast 5/19/2017. First report of C. auris from Japan in 2009

Objec&ves. Clinical Presenta&on

Fungal Infection in the ICU: Current Controversies

Candidemia: New Sentinel Surveillance in the 7-County Metro

ECMM Excellence Centers Quality Audit

Opportunistic Mycoses

Fungal Infection Pre-Infusion Data

Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, MI, USA

Optimizing antifungal dosing regimens. Joseph Meletiadis, PhD, FECMM Assistant Professor of Microbiology

ESCMID Online Lecture Library. by author

ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS

CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR

Antifungal susceptibility testing: Which method and when?

Antifungal Pharmacodynamics A Strategy to Optimize Efficacy

Fungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA

Nosocomial Candidemia in intensive care units of a tertiary care hospital, New Delhi, India

WHAT IS THE ROLE OF EMPIRIC TREATMENT FOR SUSPECTED INVASIVE CANDIDIASIS IN NONNEUTROPENIC PATIENTS IN THE ICU?

SYNERGISTIC ACTIVITIES OF TWO PROPOLIS WITH AMPHOTERICIN B AGAINST SOME AZOLE-RESISTANT CANDIDA STRAINS. PART II

TEPZZ Z9Z74_A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION

Pathogens with Intermediate Virulence Dermatophytes opportunistic Pathogens

Antifungal Update. Candida: In Vitro Antifungal Susceptibility Testing

Use of Antifungals in the Year 2008

Title: Author: Speciality / Division: Directorate:

Form 2046 R3.0: Fungal Infection Pre-HSCT Date

International Journal of Health Sciences and Research ISSN:

INFLUENCE OF ASSOCIATING NONSTEROIDAL ANTI-INFLAMMATORY DRUGS WITH ANTIFUNGAL COMPOUNDS ON VIABILITY OF SOME CANDIDA STRAINS

Efficacy of a Novel Echinocandin, CD101, in a Mouse Model of Azole-Resistant Disseminated Candidiasis

SCY-078 ECMM Symposium Cologne, Germany October 2017

Antifungal Pharmacotherapy

INFEZIONI FUNGINE E PERCORSI TERAPEUTICI IN ICU. Claudio Viscoli Professor of Infectious Disease University of Genoa

Antifungal Update 2/22/12. Which is the most appropriate initial empirical therapy in a candidemic patient?

CHAPTER 4 IMMUNOLOGICAL TECHNIQUES

Antifungal therapy in children. Adilia Warris MD PhD FRCPCH Clinical Reader Pediatric Infectious Diseases Specialist

In Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms

Candida auris. Our Misunderstood Friend JERRY KELLEY, M BA, M SN, RN, N E - BC, CPHQ, CIC

Candiduria in ICU : when and how to treat? Dr. Debashis Dhar Dept of Critical Care and Emergency Medicine Sir Ganga Ram Hospital

Updated Guidelines for Management of Candidiasis. Vidya Sankar, DMD, MHS April 6, 2017

The 8 th International CASEE Conference Warsaw University of Life Sciences SGGW May 14-16, 2017

Index. Note: Page numbers of article titles are in boldface type.

ANTIMYCOTIC DRUGS Modes of Action

Chapter 14. In Vitro Measurement of Phagocytosis and Killing of Cryptococcus neoformans by Macrophages. André Moraes Nicola and Arturo Casadevall

1* 1. Vijaya S. Rajmane, Shivaji T. Mohite

Antifungal Update 2/24/11. Which is the most appropriate initial empirical therapy in a candidemic patient?

Received 12 December 2010/Returned for modification 5 January 2011/Accepted 16 March 2011

9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure

Voriconazole October 2015 Risk Management Plan. Voriconazole

Management Strategies For Invasive Mycoses: An MD Anderson Perspective

Fungal Infection Post-Infusion Data

TOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR

Antifungal Resistance in Asia: Mechanisms, Epidemiology, and Consequences

Candida albicans 426 (64.0 ) C. albicans non-albicans

Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients

Natural and Holistic Medicine Approach in Evaluation and Treatment of Vaginal and Urinary Tract Health

Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013

Evidence-Based Approaches to the Safe and Effective Management of Invasive Fungal Infections. Presenter. Disclosures

Identification of Yeasts. Medical Mycology Training Network 15 November 2018 Dr Tan Ai Ling Department of Microbiology, Singapore General Hospital

Rapid Detection and Identification of Candidemia by Direct Blood Culturing on Solid

MALDI Sepsityper Kit

Identification of Mycoplasma spp. using MALDI-TOF Mass Spectrometry. Aric McDaniel

Micafungin, a new Echinocandin: Pediatric Development

Terapia della candidiasi addomaniale

An Automated Membrane Filtration System for Direct Gram Staining

ANTIFUNGAL AGENTS. Alison Clode, DVM, DACVO. Port City Veterinary Referral Hospital Portsmouth, New Hampshire

Sensitivity of Candida albicans isolates to caspofungin comparison of microdilution method and E-test procedure

Invasive Fungal Infections in Solid Organ Transplant Recipients

Common Fungi. Catherine Diamond MD MPH

Tissue Distribution/Penetration and Pharmacokinetics of CD101

Received 18 December 2008/Returned for modification 9 February 2009/Accepted 9 April 2009

PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI

- 1 - Cell types Monocytes THP-1 cells Macrophages. LPS Treatment time (Hour) IL-6 level (pg/ml)

Treatment and Prophylaxis

EUCAST-AFST Available breakpoints 2012

The MALDI Biotyper An In Vitro Diagnostic System (IVD) for Identification of Bacteria and Yeasts with a Global Reach

Intracellular Activity of Voriconazole, Fluconazole, and Itraconazole Against Candida albicans

Oral Candida biofilm model and Candida Staph interactions

Candida albicans. Habitat, Morphology, Cultural Characteristics, Life Cycle, Pathogenesis, Lab Diagnosis, Treatments, Prevention and Control

PREVALANCE OF CANDIDIASIS IN CHILDREN IN MUMBAI

Epidemiology of Fungal Diseases

Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan

I am against to TDM in critically ill patient

COPYRIGHT OF SPEAKER PRESENTED AT MMTN CONFERENCE, 5-6 AUG Outbreak of superbug Candida auris: Asian scenario and interventions

NOVASTREAK. Microbial Contamination Monitoring Device TYPICAL CULTURAL MORPHOLOGY Baird Parker Agar. S. aureus growth on Baird Parker Agar

Transcription:

VIRULENCE FACTORS AND SUSCEPTIBILITY OF CANDIDA SPP. CAUSATIVE AGENTS OF NEONATAL INFECTIONS Nikola Stojanović, Predrag Stojanović, Suzana Otašević, Valentina Arsić-Arsenijević

What do we know? - Third most common microorganism isolated from obligatory sterile body sites - High mortality in neonates, especially in those with low birth weight (LBW) - Numerous risk factors: indwelling devices, broad-spectrum antibiotics, total parenteral nutrition, corticosteroids, gastrointestinal surgery, and/or history of fungal colonization (Chicella et al., 2011, J Pediatr Pharmacol Ther.). - Empiric antifungal therapy results in improved survival

What we still need to learn? -What are the most important virulence factors? -Can we predict the disease progression based on virulence factors? -Are the predisposing factors for disease development reliable?

AIMS: -Determine Candida spp. from blood cultures in neonates with sepsis -Evaluate their susceptibility -Determine virulence characteristics -Correlate the obtained data with collected patients data

Materials and methods -Patients data collection from the Clinical Centre Niš, Department of neonatology included: -Age, -Gender, -Underlaying diseases, -Hospitalization related data, -Therapy applied, -Disease outcome.

Candida spp. determination -Blood culture cultivation in Bactec Mycosis Media (BACTEC 9120 system), -Culturing and interpretation of colored colony morphology (HiCrome Candida Differential Agar), -Interpretation of biochemical tests for clinical yeast identification (Fungifast, ELITech), -Matrix-assisted laser desorption ionization time of flight (MALDI-TOF) mass spectrometry

Susceptibility determination Antifungal susceptibility testing was performed using Micronaut-AM MHK-2 plates (Merlin Diagnostika, Bornheim, Germany) that included: -amphotericin B (AmB) (0.03-16 μg/ml), -fluconazole (FLUC) (0.125-128 μg/ml), -5-fluorocytosine (5-FLU) (0.06-32 μg/ml), -itraconazole (ITR) (0.03-4 μg/ml), -posaconazole (POS) (0.015-16 μg/ml), -voriconazole (VOR) (0.015-16 μg/ml), -micafungin (MCF) (0.01-16 μg/ml), -caspofungin (CAS) (0.01-16 μg/ml), -anidulafungin (ADF) (0.01-16 μg/ml)

Biofilm formation under static conditions -Incubation performed for 48 h at 37 C in RPMI containing 8% glucose, -Staining was performed with 0.4% (w/v) crystal violet solution, -Biofilm mass was distained with 96% (v/v) ethanol, -The ethanol solution absorbance was recorded at 595 nm, -Production classification: non-, weak, moderate and strong production Stepanović et al., (2000).

Rat macrophages isolation and preparation -Wistar rats, male, 3 month old, injected with thioglicolic acid to elicit macrophages into the peritoneal cavity -The peritoneal lavages obtained from animals were centrifuged (1200 rpm, 10 min at 4 ºC) -Cell viability was determined by the trypan blue dye exclusion method -Cell suspensions were adjusted to 2.5 10 6 cells/ml -All experiments were preformed according to Ethical regulations (EU Directive of 2010;2010/63/EU)

Macrophage viability and function -Incubation of macrophages with C. albicans or C. lusitaniae for 24 h -Determination of macrophage killing activity using MTT assay -Macrophage killing is expressed as % of viable macrophages after 24 h incubation with C. albicans or C. lusitaniae

Myeloperoxidase activty -Incubation of macrophages with C. albicans or C. lusitaniae for 24 h MPO + H 2 O 2 -MPO activity was presented as optical density (OD) increase compared to untreated cells x 1000

Candidacidal activity of macrophages -Incubation of macrophages with Candida suspensions was preformed during 1 h -After 24 h of incubation at 37 C, viable counting of survivor cells (number of colonies) was performed. -The results are expressed as hundreds of cells per ml.

Phagocytosis assay -Done on microscopic slides with previously adhered macrophages that were covered by Candida suspension (90 minutes at 25 C) and stained with Giemsa -The phagocytic index was determined by calculating the average number of yeast cells engulfed by or adhering to 100 macrophages. -The percentage phagocytosis and the phagocytic index were calculated following the formula: percentage phagocytosis = number of positive cells per 100 cells observed x phagocytic index - average number of yeast cells engulfed by a positive cell.

OUR FINDINGS

Patients characteristics No 1 No 2 Isolated strain C. albicans C. lusitaniae Age (days) 17 15 Gender M M Disease LBW LBW Outcome Cured Cured

Strain/patients characteristics No 1 No 2 Isolated strain C. albicans C. lusitaniae Resistance None None Therapy applied FLUC AmB Hyphal transition + -

Biofilm production ability Borrowed from Machado Vila et al., 2016 Risk factors: High blood glucose Central venous catheter Urinary catheter C. albicans C. lusitaniae Strong Weak - - - +

Macrophages produce MPO produce MPO Candida yeast Macrophages kill Candida C. albicans hyphae Non-lytic expulsion Macrophages engulf Candida Peritoneal macrophages Candida kills macrophages

Strain virulence characteristics No 1 No 2 Isolated strain C. albicans C. lusitaniae Macrophage killing activity (%) 78 76 MPO activity (ODx1000) 427 364 Candidacidal activity of macrophages (x 10 2 cells) Macrophage phagocytosis assay (index) 19 26 5 27

Conclusions -The results of the present study are only preliminary and although there are no differences, at least clearly visible ones, among two neonates the virulence characteristics of the two isolated strains exist. -The authors are aware of the low number of strains that were evaluated and compared, but one cannot diminish the importance of the results obtained here. -Obtained results indicate that NAC, in this case C. lusitaniae, is more sensitive to the influence of host cells, while C. albicans causes a more intense reaction of host cells